Alliance Global Partners raised the firm’s price target on PDS Biotechnology to $7 from $5 and keeps a Buy rating on the shares. The firm re-included the double-combination into its valuation. The Phase 3 VERSATILE-003 double-combination trial is on track for Q4 initiation, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PDSB:
- PDS Biotechnology Enhances and Modulates Stock Sales Agreement
- PDS Biotech Provides Business Update and Reports Second Quarter 2024 Financial Results
- PDS Biotechnology reports Q2 EPS (23c), consensus (34c)
- PDSB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024
Questions or Comments about the article? Write to editor@tipranks.com